Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates RANKL inhibition limits fibrous dysplasia progression, highlighting potential treatment avenues.
In brief: The effect of RANKL inhibition on fibrous dysplasia development is explored here using a mouse model of a fibrous dysplasia-like disorder. Anti-mouse RANKL monoclonal antibody treatment prevented the development and growth of lesions. However, after discontinuation of anti-mouse RANKL antibody treatment, disease progression resumed and newly formed bone was remodelled into fibrous dysplasia.
No takes yet. Share an insight, caveat, or question.
Palmisano et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: